Humacyte Secures $60 Million in Oversubscribed Offering to Advance Bioengineered Tissue Platform
Key Insights
Humacyte raised $60 million through an oversubscribed registered direct offering with institutional investors, selling 28.4 million shares and warrants at $2.11 per unit.
The company's acellular tissue engineered vessel (ATEV) received FDA approval for extremity vascular trauma (search) in December 2024, marking a significant regulatory milestone.
ATEVs are currently in late-stage clinical trials for arteriovenous access in hemodialysis and peripheral artery disease (search) applications.
Humacyte, Inc. (Nasdaq: HUMA) announced the completion of a $60 million oversubscribed registered direct offering with institutional investors, providing capital to advance its bioengineered human tissue platform. The Durham, North Carolina-based biotechnology company sold 28,436,018 shares of common stock and an equal number of warrants at $2.11 per unit.
The warrants will become exercisable 180 days following issuance, carry an exercise price of $2.11 per share, and expire on April 7, 2031. D. Boral Capital LLC (search) served as the exclusive placement agent for the offering, which is expected to close on October 8, 2025.
FDA-Approved Bioengineered Vessel Technology
Humacyte's lead product, the acellular tissue engineered vessel (ATEV), achieved a significant regulatory milestone with FDA approval for extremity vascular trauma (search) treatment in December 2024. This approval represents the first commercialization of the company's platform technology for developing universally implantable bioengineered human tissues.
The ATEV technology addresses critical medical needs across multiple vascular applications. Beyond the approved trauma indication, ATEVs are currently in late-stage clinical trials for arteriovenous (AV) access in hemodialysis patients and peripheral artery disease (search) (PAD) treatment.
Regulatory Recognition and Pipeline Development
The company's 6mm ATEV for AV access in hemodialysis became the first product candidate to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also secured FDA Fast Track designation. Additionally, Humacyte's 6mm ATEV for urgent arterial repair following extremity vascular trauma (search) and for advanced PAD have both received RMAT designations.
The ATEV technology has gained recognition beyond the FDA, receiving priority designation for vascular trauma treatment from the U.S. Secretary of Defense, highlighting its potential military and emergency medicine applications.
Expanding Therapeutic Applications
Humacyte's preclinical development pipeline extends beyond vascular applications, with programs underway in coronary artery bypass grafts, pediatric heart surgery, and treatment of type 1 diabetes (search). The company is also exploring multiple novel cell and tissue applications as part of its broader platform strategy.
The biotechnology platform focuses on developing acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. The company's approach involves creating universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to transform medical practice.
Commercial Strategy and Market Position
As a commercial-stage biotechnology platform company, Humacyte manufactures its bioengineered tissues at commercial scale. The company has branded its FDA-approved ATEV product as Symvess (search) for the extremity vascular trauma (search) indication.
For applications beyond the FDA-approved extremity vascular trauma (search) indication, the ATEV remains an investigational product pending regulatory approval. The company continues to advance its clinical development programs while building manufacturing capabilities to support both clinical trials and commercial needs.